

NEWS RELEASE

NEWS RELEASE

CONTACT: Andrew Bright
+ 1 (484) 530 3922
andrew.bright@oncure.com
www.oncure.com

Long-term cancer survival data utilizing ONCURE's OncoSeed™ re-inforces brachytherapy's position as standard of care for treating prostate cancer.

Philadelphia (April 28, 2004) — As the global leader in minimally invasive prostate cancer treatment ONCURE™ is committed to research and development that results in improved outcomes for patients treated with prostate brachytherapy. Fifteen-year data exclusively utilizing ONCURE's OncoSeed (Iodine-125 Seeds) were recently presented by John Blasko MD, Medical Director of the Seattle Prostate Institute at the Institute's 7th annual Seattle Prostate Institute meeting. "At fifteen years after Iodine-125 brachytherapy, only 4% of patients had died from prostate cancer", said John Blasko. "The release of this data further confirms brachytherapy as a leading prostate cancer treatment option".

"The presentation of long term survival data that's only available for ONCURE's Iodine-125 products will encourage other physicians to offer prostate brachytherapy to their patients", said John Jeans, Chairman of ONCURE. He added, "Advances such as ONCURE's RAPID Strand™, which is routinely used by the Seattle Prostate Institute, are expected to improve results even further".

Long-term data supporting prostate brachytherapy with RAPID Strand were presented at the European Association of Urology meeting in Vienna. Mr. Stephen Langley, Consultant Urologist at St Luke's Cancer Center, Guildford, UK, presented results of their five-year follow-up, with 93% of patients disease free at this time. These results indicate that prostate brachytherapy has now become a routine and successful option for patients in Europe as well as the US.

"Our commitment to prostate brachytherapy is exemplified by our continued support of centers of excellence that evaluate and present long-term data," said James McGlone,

CEO and President of ONCURA. “The Seattle Prostate Institute, Chicago Prostate Cancer Center, New York Prostate Institute and St. Luke’s in the UK are just a few of the numerous groups that will publish their long-term RAPID Strand or OncoSeed experience over the coming year”.

ONCURA, a business of Amersham plc, was created through the merger of Amersham’s brachytherapy business with Galil Medical Ltd’s urology business. Headquartered in the United States, ONCURA operates as an independent business of Amersham plc, with Galil holding a minority position of 25 percent. ONCURA has a major presence in the treatment of prostate cancer. On April 8, 2004, General Electric (GE) completed its previously announced acquisition of Amersham.

#

Notes to Editor

Brachytherapy involves the placement of small radioactive seeds in the prostate, sparing patients from the more invasive radical prostatectomy surgery.

RAPID Strand is an innovative brachytherapy product that is associated with improved radiation delivery; which in turn correlates with effective therapy.

Contact Information

Seattle Prostate Institute	www.seattleprostateinst.com
Chicago Prostate Cancer Center	www.prostateimplant.com
New York Prostate Institute	www.nyprostate.org